More than 20 listed companies respond to the impact of mycoplasma pneumonia

"Mycoplasma pneumonia" has been on the hot search recently, and the supply of related diagnostic and therapeutic drugs has also aroused concern.

On October 16, surging journalists found on the interactive platform of Shanghai Stock Exchange and Shenzhen Stock Exchange that since October, "mycoplasma pneumonia" has become the topic of many investors' questions to listed companies. At present, more than 20 A-share pharmaceutical companies have responded, involving vaccines, testing reagents, therapeutic drugs and other fields. Some companies confirm that they have related therapeutic drugs, but most companies also remind them to use drugs according to the doctor's advice or refer to the instructions because of the prescription drugs involved.

What is mycoplasma pneumonia? How to detect treatment?

The full name of mycoplasma pneumonia is mycoplasma pneumoniae pneumonia (MPP), which refers to the pulmonary inflammation caused by mycoplasma pneumoniae infection, which can affect bronchi, bronchioles, alveoli and pulmonary interstitium.

According to an article published on October 14 on the WeChat official account of "Huashan Infection", Mycoplasma pneumoniae is a special micro organism. This microorganism spreads all over the world and can cause transmission on different scales. Its transmission mode is similar to the common cold. In most cases, some people may only have mild cold symptoms, but in a few cases, it can indeed cause pneumonia.

According to the Guidelines for the Diagnosis and Treatment of Mycoplasma Pneumoniae Pneumonia in Children (2023 Edition) issued by the National Health Commission in February 2023, MPP is mostly seen in children aged 5 years and above, but children under 5 years old can also get sick. The main clinical manifestations are fever and cough, which may be accompanied by headache, runny nose, sore throat, earache, etc. Fever is mainly moderate to high, and persistent high fever indicates severe illness. The cough is more severe and can be similar to whooping cough. Some children have wheezing, which is more common in infants. A few MPPs can develop into critical illness.

Source: Guidelines for Diagnosis and Treatment of Mycoplasma Pneumoniae Pneumonia in Children (2023)

Symptoms alone cannot determine whether it is mycoplasma pneumonia. The above guidelines suggest that MP culture is the "gold standard" for the diagnosis of MP infection, but because MP culture requires special conditions and grows slowly, it is difficult for clinical diagnosis. MP nucleic acid detection includes MP-DNA or MP-RNA detection with high sensitivity and specificity, which is suitable for early diagnosis of MPP.

For the treatment of mycoplasma pneumonia, the above guidelines pointed out that mild cases do not require hospitalization, full rest and energy intake to ensure water and electrolyte balance. Take antipyretics correctly. For those who have high coagulation and are forbidden to eat, water and electrolyte should be added. If the dry cough obviously affects the rest, antitussive drugs can be used as appropriate.

In the anti MP treatment, the guidelines clearly indicate that macrolide antibiotics are the first choice for the treatment of MPP, including azithromycin, clarithromycin, erythromycin, roxithromycin and acetyl kitasamycin. New tetracycline antibiotics and quinolones are substitutes.

More than 20 listed companies responded to the drug supply of mycoplasma pneumonia

According to the previous report of chinanews. com, recently, according to media reports, the number of children receiving medical clinics in children's hospitals in Beijing, Shanghai, Guangzhou and other places increased, mainly due to mycoplasma pneumonia infection. In this context, many investors asked the listed companies whether there were any drugs for the treatment of mycoplasma pneumonia, or whether some of its products could be used for the treatment of mycoplasma pneumonia, and whether the recent sales increased.

The surging journalists found that, as of press release, more than 20 listed companies had responded to questions related to mycoplasma pneumonia. Some companies confirmed that they had related therapeutic drugs. As prescription drugs were involved, most companies also reminded them to use drugs according to medical advice or refer to the instructions. Some companies said that they had no relevant products, while others said that they had relevant product approval documents but did not produce and sell them.

Some questions about "mycoplasma pneumonia" on the interactive platform

Zhejiang Pharmaceutical (600216) replied that whether the company could use narofloxacin malate for the treatment of mycoplasma pneumonia, according to the company's instructions for narofloxacin malate capsules, this product is suitable for the treatment of patients sensitive to narofloxacin, including Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Klebsiella pneumoniae, Mycoplasma pneumoniae Community acquired pneumonia in adults (≥ 18 years old) caused by chlamydia pneumoniae and Legionella pneumophila. Please note that this product is a prescription drug and should be used under the guidance of a doctor.

When asked whether there are any drugs for mycoplasma pneumonia in children, Huluwa (605199) responded that the company's Xiaoer Feire Kechuan Granule (4g) was recommended as one of the drugs for treating mycoplasma pneumonia in children by the series of journals of the Chinese Pharmaceutical Association Modern Medicine and Clinical Medicine and the Expert Consensus on Integrated Diagnosis and Treatment of Mycoplasma Pneumonia in Children (formulated in 2017). In addition, the company has azithromycin injection, which can be used to treat mycoplasma pneumonia.

Sunflower Pharmaceutical (002737) also said in its response that the respiratory system medication is the company's key drug field, and the company has a number of adult and child cough, anti-inflammatory, expectorant products, and specific medication needs to comply with medical advice.

Fu'an Pharmaceutical (300194) said that the company has approval documents for anti infective drugs that can be used for the treatment of mycoplasma pneumonia. Macrolides are generally used for mycoplasma pneumonia. The company has approval documents for azithromycin tablets, dispersible tablets, erythromycin enteric coated tablets, etc. At present, it has not produced and sold the above drugs; Secondly, quinolones and tetracyclines can also be used to treat related diseases. The company is producing and selling levofloxacin tablets, injections, tegacycline and other drugs. At present, the sales of related products are small, and the amount of business income is small. The specific drugs used to treat related diseases need professional judgment by doctors in combination with the specific clinical symptoms of patients.

Jincheng Pharmaceutical (300233) said that according to the diagnosis and treatment guidelines, its subsidiary Jincheng Suzhi can be used for mycoplasma pneumonia, including quinolones levofloxacin tablets and macrolides relying erythromycin tablets. At the same time, the company has arranged a number of series of products for the treatment of mycoplasma pneumonia, including tetracycline Doxycycline, minocycline injection, macrolide Clarithromycin Lactate and other varieties. At present, Clarithromycin Lactate has completed the registration of API and is in the stage of review and approval; Clarithromycin Lactate for Injection has been declared as a class 3 clinical validation drug, and is currently in the review and approval stage. The company will pay attention to the approval progress in time and actively promote the drug approval work.

Huaren Pharmaceutical (300110) said that the company's quinolones such as levofloxacin injection could be used to treat pneumonia caused by mycoplasma pneumoniae. Levofloxacin injection is mainly used to treat the following mild, moderate and severe infections in adults (≥ 18 years old) caused by sensitive strains of the following bacteria. It includes the following infections: hospital acquired pneumonia, community acquired pneumonia, acute bacterial sinusitis, acute bacterial attack of chronic bronchitis, complex skin and skin structure infection, non complex skin and skin soft tissue infection, chronic bacterial prostatitis, complex urinary tract infection, acute pyelonephritis Non complex urinary tract infection and inhalation anthrax (after exposure), etc.

Fengyuan Pharmaceutical (000153) said that its subsidiary Tushan Pharmaceutical had produced azithromycin capsules. Azithromycin is a macrolide antibiotic. Please refer to the product manual for specific indications.

Teyi Pharmaceutical (002728) said that the company has a wide range of drugs, including antitussive, antipyretic, antibiotic, antiviral, digestive system, etc. The company's erythromycin enteric coated tablets, erythromycin dependent tablets, roxithromycin capsules, azithromycin tablets and azithromycin granules are suitable for the treatment of mycoplasma pneumonia. The above drugs are currently in normal production and sales.

With regard to the impact of related drugs on the company's performance, Fu'an Pharmaceutical (300194) said that the company has approval documents for anti infective drugs that can be used for the treatment of mycoplasma pneumonia. Macrolides are generally used for mycoplasma pneumonia. The company has approval documents for azithromycin tablets, dispersible tablets, erythromycin enteric coated tablets, etc. At present, there is no production and sales of the above drugs; Secondly, quinolones and tetracyclines can also be used to treat related diseases. The company is producing and selling levofloxacin tablets, injections, tegacycline and other drugs. At present, the sales of related products are small, and the amount of business income is small.

There are also pharmaceutical enterprises that say that there are no drugs for treating mycoplasma pneumonia. For example, Hongyuan Pharmaceutical (301246) responded that the products of the company, such as Pudilan anti-inflammatory tablets, Kechuanning granules, Shedan Chuanbei liquid, can effectively treat and relieve symptoms such as throat pain and cough caused by mycoplasma pneumonia, and there are no drugs specifically for treating mycoplasma pneumonia. Please follow the doctor's advice or consult a licensed doctor or pharmacist when buying or taking medicine.

It is worth mentioning that some investors also asked whether the company has mycoplasma pneumonia vaccine. In this regard, Watson Biology (300142) said that the company's pneumonia series vaccine is used to prevent infectious diseases caused by the serotype pneumococci corresponding to the product. At present, the company has not carried out research and development of vaccine against mycoplasma infection.

In addition, Innotel (688253) was asked whether there are mycoplasma pneumonia detection products. The company responded that its products mainly focus on respiratory pathogen detection. At present, the company has 26 domestic product registration certificates in the field of respiratory pathogen detection, all of which are three types of medical device registration certificates. Among them, mycoplasma pneumonia detection related products include mycoplasma pneumonia IgM antibodies There are many products, such as chlamydia pneumoniae IgM antibody, respiratory syncytial virus IgM antibody, adenovirus IgM antibody, Coxsackie virus group B IgM antibody joint detection kit (colloidal gold method), influenza A virus, influenza B virus, mycoplasma pneumoniae antigen detection kit (colloidal gold method), mycoplasma pneumoniae antibody detection kit (colloidal gold method), and so on. The income of related products is affected by market demand, hospital coverage and other factors.

key word: pneumonia mycoplasma High fever a bronchial tube